This application requests Cancer Center Support Grant funding for the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa. This is the second CCSG competitive renewal for the HCCC. The HCCC functions administratively as a matrix Cancer Center with 189 Center members from six colleges and 36 departments across the University. It leverages the resources and expertise provided by the medical center and across the University to support and strengthen transdisciplinary cancer research. The HCCC has extensive support from both the institution and via private support. The members of the HCCC have $74.2 million in total annual cancer-related, peer-reviewed, external research support. Of this, over $20.4 million comes from the NCI. The HCCC is organized into six research programs that are each designed to be translational in nature. Together they encompass a broad spectrum of strength in basic laboratory, clinical and population research. These programs are 1) Cancer Immunology &Immunotherapy, 2) Cancer Signaling and Experimental Therapeutics, 3) Free Radical Cancer Biology, 4) Tumor Imaging, 5).Cancer Epidemiology, and 6) Cancer Genomics and Cell Growth. In addition to the Administrative Core, the HCCC supports eleven shared resources including: 1) DNA, 2) Gene Transfer Vector, 3) Radiation and Free Radical Research, 4) Flow Cytometry, 5) Central Microscopy Research Facility, 6) Small Animal Imaging, 7) Tissue Procurement 8) Bioinformatics, 9) Population Research, 10) Biostatistics, and 11) Clinical Trials Support. Through these programs and cores, and an effective organizational structure, the HCCC enhances interactions, supports collaborations, and sets the direction of future cancer research activities at the HCCC.
The Cancer Center Support Grant supports the infrastructure of the Holden Comprehensive Cancer Center. This infrastructure allows the Center to foster excellence in research across a broad spectrum of scientific areas relevant to cancer, and translate those advances to the clinic with the goal of reducing the morbidity and mortality of cancer.
|Chrisman, Matthew; Nothwehr, Faryle; Janz, Kathleen et al. (2015) Perceived Resources and Environmental Correlates of Domain-Specific Physical Activity in Rural Midwestern Adults. J Phys Act Health 12:962-7|
|Chrisman, Matthew; Nothwehr, Faryle; Yang, Ginger et al. (2015) Environmental influences on physical activity in rural Midwestern adults: a qualitative approach. Health Promot Pract 16:142-8|
|Makkouk, Amani; Weiner, George J (2015) Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 75:10-May|
|Naderi, Ali (2015) Coagulation factor VII is regulated by androgen receptor in breast cancer. Exp Cell Res 331:239-50|
|McDowell, Bradley D; Chapman, Cole G; Smith, Brian J et al. (2015) Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg 261:740-5|
|Ponto, Laura L Boles; Menda, Yusuf; Magnotta, Vincent A et al. (2015) Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. Int J Geriatr Psychiatry 30:587-94|
|Chrischilles, Elizabeth A; McDowell, Bradley D; Rubenstein, Linda et al. (2015) Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: the CanCORS disease-free survivor follow-up study. J Cancer Surviv 9:269-78|
|Makkouk, Amani; Joshi, Vijaya B; Wongrakpanich, Amaraporn et al. (2015) Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J 17:184-93|
|Bhama, A R; Charlton, M E; Schmitt, M B et al. (2015) Factors associated with conversion from laparoscopic to open colectomy using the National Surgical Quality Improvement Program (NSQIP) database. Colorectal Dis 17:257-64|
|Hoover, Andrew C; Milhem, Mohammed M; Anderson, Carryn M et al. (2015) Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial. Head Neck 37:722-6|
Showing the most recent 10 out of 187 publications